ProCE Banner Activity

Intermediate Atypical Carcinoma: Novel Histological Subtype of mCRPC in Patients Resistant to Androgen Receptor Agonists

Slideset Download
Conference Coverage
Biopsy study identified an important new histologic subtype, which when combined with SCNC, represents the largest group of AR therapy–resistant patients.

Released: June 05, 2015

Expiration: June 03, 2016

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

AstraZeneca

Bayer Healthcare Pharma

Bristol Myers Squibb

Celgene

Genentech BioOncology

Incyte

Novartis Pharmaceuticals Corporation